Compare CVS Health Corp (CVS) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs iShares Core S&P 500 ETF — how do they compare? CVS Health Corp trades at $86.89 (market cap $112.29B), while iShares Core S&P 500 ETF trades at $781.57 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 8× CVS Health Corp's market cap, and CVS Health Corp pays a 3.03% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and iShares Core S&P 500 ETF for 46 Days on average.
| CVS | IVV | |
|---|---|---|
Market Cap | $112.29B | $897.20B |
Volume | 7,763,676 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $782.58 |
52-Week Low | $70.08 | $634.93 |
Typical Hold Time | 83 Days | 46 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
IVV, tracking the S&P 500, trades at $779.68, down 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights mixed S&P 500 valuation signals, with earnings growth expected to slow in 2027 but historical seasonal patterns suggesting potential upside. The ETF's fundamentals reflect the index's aggregate metrics, with no company-specific financials reported.
Outlook remains cautiously optimistic given the bullish technical bias and index-level support, though risks include concentration in top holdings and macroeconomic headwinds. Investors gain diversified exposure to large-cap U.S. equities, but should monitor earnings trends and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
